Comparing preventive antibiotics for liver transplant patients carrying resistant bacteria
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests whether giving antibiotics chosen specifically for your resistant bacteria before a liver transplant can prevent infections better than the usual standard antibiotics. It aims to improve recovery and lower the risk of serious infection after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled to receive a liver transplant.
- You have tested positive for carbapenemase-producing Enterobacterales (CPE), a type of resistant bacteria, without having an active infection.
- You do not have an active infection from any Gram-negative bacteria at the time of transplant.
- You are not allergic to beta-lactam antibiotics (like penicillin or cephalosporins).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This trial checks if monitoring antibiotic levels in the blood can help doctors give the right dose to liver transplant patients with serious bacterial infections. The goal is to make the treatment work better.
This study compares two strong antibiotics to see which one works better for people with liver failure who get a hospital-acquired infection caused by resistant bacteria. The two drugs are ceftazidime-avibactam and a higher dose of meropenem given as an extended infusion.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.